Startups
BactoKind is a natural product for the dietary alleviation of Infant Colic. This is the lead candidate of SURI BioTech, and it will be the first natural microbial solution for infant colic relying on a clear mode of action and it will improve infant and family well-being.
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 3, 2023 | Swissnex San Francisco Propel Swiss Health Startups into the US Market | |
| Apr 19, 2023 | Ten biotech startups head to Boston | |
| Jul 4, 2022 | Four startups each receive CHF 150’000 | |
| Mar 24, 2022 | 16 Startups Advance to the Next Round of the W.A. de Vigier Awards |
Reviews 0
FAQ about SURI BioTech GmbH
What has the press written about SURI BioTech GmbH?
Parsers VC has collected 5 articles mentioning SURI BioTech GmbH, among them “Swissnex San Francisco Propel Swiss Health Startups into the US Market” (Jul 3, 2023) and “Ten biotech startups head to Boston” (Apr 19, 2023).
Is SURI BioTech GmbH still active?
Yes, SURI BioTech GmbH is active; its latest activity on Parsers VC dates from Apr 8, 2024.